This study is in progress, not accepting new patients
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- by Robin Kate Kelley
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCSF
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Eli Lilly and Company
- Links
- A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
- ID
- NCT02711553
- Phase
- Phase 2 research study
- Study Type
- Interventional
- Participants
- At least 309 people participating
- Last Updated